Intra-arterial Liver Isolation Chemotherapy via an Implantable Vascular Access Device to Facilitate Repeated Vascular Access for Patients with Hepatic Metastases from Colorectal Cancer (The SYS-CAPLIOX Trial)

Introduction: The SYS-CAPLIOX trial uses an implantable vascular access device (AVAS®) for repeated liver isolation intra-arterial oxaliplatin (LIOX) patients with inoperable colorectal cancer metastases (CRCLM). Similar to selective internal radiation therapy (SIRT), transarterial chemoembolization (TACE) and hepatic arterial infusion (HAI), the LIOX technique negates puncture has reduced surgical morbidity systemic leak. Methods: Using standard endovascular techniques balloon catheters, AVAS allows simultaneous multi-catheter into arteries administer blood supply temporarily obstructed. portal flow is indirectly obstructed via coeliac axis superior mesenteric balloons while venous outflow positive-end-expiratory-pressure. Results: previously been shown be safe feasible in a pilot study treating 10 salvage setting, progressive disease, stable partial response seen 4,3, 3 respectively. With EU TGA regulatory approval, implanted off-trial patient CRCLM no adverse effect, malfunction or use error. received 5 infusions after which was successfully explanted. Conclusion: SIRT, TACE, HAI lack of control can lead significant washout infused agents pulmonary system. treatment full absorption anti-cancer that may thwarted by intravenous administration. currently available use. registered (ACTRN12617001268336) commenced recruitment November 2019.